Andernach – LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company, has been selected as a Concept Stage winner for two projects in the #PatchForwardPrize, a $50 million challenge by the Biomedical Advanced Research and Development Authority (BARDA) to advance microneedle patch-based RNA vaccine technologies.
The Patch Forward Prize, a part of the Project NextGen initiative led by BARDA, aims to accelerate next-generation vaccine technologies. By fostering partnerships between vaccine developers and delivery platform innovators, the competition drives progress from concept to clinical stages, paving the way for transformative advancements in global health. The prizes, totaling $2 million each, will be shared between LTS and its partners.
The awarded projects bring together LTS’s proprietary dissolvable Microneedle Array Patch (MAP) technology with mRNA vaccines from two partners, BioNet, a biotech manufacturer specializing in genetically engineered vaccines, and PopVax, an Indian full-stack biotechnology company developing broadly-protective mRNA vaccines using machine learning-enabled computational protein design.
Both projects aim to address critical challenges in vaccine stability, delivery, and adaptability, with the potential to improve patient access and compliance. The focus will be on seasonal influenza vaccines, with the ability to pivot to pandemic strains if necessary.
BioNet’s approach tackles the ongoing challenge of influenza strain variability by developing a trivalent seasonal influenza mRNA vaccine (mIV3) that targets conserved regions of the hemagglutinin (HA) and neuraminidase (NA) proteins from dominant H1N1, H3N2, and B influenza viruses. These mRNA constructs have been carefully selected to elicit broad protective immune responses against seasonal influenza.
PopVax is leading the effort to develop a seasonal influenza vaccine built on their novel mRNA-encoded immunogen display architecture and LNP platform. PopVax’s immunogen design and display approach boosts the elicited strain-specific antibody response by as much as 250x in mice in comparison with a leading approved influenza vaccine, leading to significantly lower dosage requirements. This approach also elicits a broader immune response, including robust antibody titer against pandemic H5N1 influenza, a rising threat in the United States, despite not encoding an H5N1-specific immunogen.
LTS CEO Bas van Buijtenen commented on the company’s selection as a Concept Stage winner: “As a front-runner in drug delivery, we are passionate about solutions that provide better outcomes and a better patient experience. We are grateful and proud that BARDA’s Patch Forward Prize provides an opportunity for BioNet, PopVax, and LTS to create a breakthrough in vaccine administration. We look forward to delivering on the promise of the combination of our technologies through our joint programs.”
Additionally, Dr. Frank Theobald, Head of MAP Program at LTS, stated: “LTS’s Microneedle-Array-Patch (MAP)-Program is proud to have received these two awards together with our partners PopVax and BioNet, with their innovative mRNA technologies. The BARDA Patch Forward Prize allows for the combination of two breakthrough technologies to better prepare for future pandemics. The financial support from BARDA will help advance the MAP technology towards commercialization, addressing an unmet medical need and offering the opportunity for self-administration, as well as lowering the cold-chain requirements for mRNA.”
About LTS
LTS is a trusted technology partner for the pharmaceutical industry, developing and manufacturing innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”), as well as wearable drug delivery devices (“OBDS”). The company’s commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 40 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded and proprietary, LTS-funded projects. The company maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Microneedle Array Patches (“MAP”) for the transdermal delivery of small and large molecules, biological actives, and vaccines. With its SorrelTM wearable drug delivery platform, LTS offers patient-friendly solutions for complex drug delivery at home. Founded in 1984, LTS operates today from four sites: in Andernach, Germany, West Caldwell, NJ, USA, St. Paul, MN, USA, and Netanya, Israel. The company also has a representative office in Shanghai, China.
For further information, please contact:
Dr. Iris Schnitzler: +49 2632 992589;
iris.schnitzler@ltslohmann.com;
Distributed by https://pressat.co.uk/
